fosmanogepix fosmanogepix fosmanogepix is an experimental antifungal drug being developed by pfizer. it is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis. fosmanogepixclinical dataother namesapx001, apx-001atc codenonelegal statuslegal status investigational identifiers iupac name benzyl}-1,2-oxazol-5-yl)-1-pyridiniumyl]methyl hydrogen phosphate cas number2091769-17-2pubchem cid44123754drugbank15183chemspider64853722unii1xq871489pkeggd11694chemical and physical dataformulac22h21n4o6pmolar mass468.406 g·mol−13d model (jsmol)interactive image smiles c1ccnc(c1)occ2ccc(cc2)cc3cc(on3)c4ccc(c4n)cop(=o)(o) inchi inchi=1s/c22h21n4o6p/c23-22-19(4-3-11-26(22)15-31-33(27,28)29)20-13-18(25-32-20)12-16-6-8-17(9-7-16)14-30-21-5-1-2-10-24-21/h1-11,13,23h,12,14-15h2,(h2,27,28,29)key:jqonjqkkvahonf-uhfffaoysa-n fosmanogepix is a prodrug and is converted into the active drug form, manogepix, after administration. manogepix targets the inositol acyltransferase gwt1 (glycosylphosphatidylinositol-anchored wall protein transfer 1), an enzyme in the glycosylphosphatidylinositol (gpi) anchor biosynthesis pathway. inhibiting this enzyme prevents the fungi from producing certain proteins essential to its life cycle. this mechanism of action is novel; therefore, if approved, fosmanogepix would become a first-in-class medication.